<DOC>
	<DOC>NCT00369993</DOC>
	<brief_summary>Spacers are used by people with respiratory diseases who have problems using MDIs (metered dose inhalers). This study used fluticasone propionate/salmeterol to look at the pharmacokinetic profiles produced by different spacers in their washed and un-washed states.</brief_summary>
	<brief_title>Spacer Comparison In Adult Asthmatics</brief_title>
	<detailed_description>A randomised, open label, five-way crossover study to assess the systemic exposure of fluticasone propionate and salmeterol from SERETIDE™/ADVAIR™ 250 HFA MDI without spacer and with AeroChamber-Max spacer and VOLUMATIC™ both in their washed and unwashed states in adult subjects with mild or intermittent asthma.</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criteria: Nonsmoking with a BMI of 19 30 Diagnosed with mild or intermittent asthma and taking medication for it. Exclusion criteria: Taking oral corticosteroids or inhaled fluticasone propionate Have certain medical conditions or are not otherwise healthy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>spacer</keyword>
</DOC>